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Abstract
Introduction. The main indication for ablation of supraventricular tachycardia is symptomatic relief. Generic measures of
quality of life are not suitable for direct evaluation of arrhythmia-related symptoms, and a speciﬁc tool is needed. The
questionnaire U22 quantiﬁes symptoms associated with arrhythmic events. It uses discrete 0–10 scales for quantiﬁcation of
inﬂuence of arrhythmia on well-being, intensity of discomfort, type of dominant symptom, and a time aspect that summarizes
duration and frequency of spells. We evaluated U22 in a well deﬁned group of patients with paroxysmal supraventricular
tachycardia, undergoing an intervention with a distinct end-point and a high success rate.
Methods. Symptoms in patients withaccessory pathway and atrioventricular nodal re-entrant tachycardia scheduled for ablation
were measured with U22 and SF-36 on admission. The evaluation was repeated after 6 months.
Results. Altogether 58 patients successfully ablated in 2006–2008 completed the four forms (U22 and SF-36 at base-line and
follow-up, 210 ± 35 days after ablation). The score for well-being (0–10; 10 being best) increased from 5.9 ± 2.6 to 7.9 ±
1.9 (P < 0.0005). The score for arrhythmia as cause for impairment in well-being (0–10; 10 being highest) decreased from 7.5 ±
2.8 to 2.0 ± 3.1 (P < 0.0005). The time aspect score (0–10) decreased from 4.7 ± 1.5 to 1.4 ± 1.8 (P < 0.0005). The two
SF-36 summary measures PCS and MCS increased from 46.9 ± 9.4 to 48.4 ± 10.7 and from 44.9 ± 12.5 to 49.1 ±
9.9 (P = 0.04 and 0.002).
Conclusion. After successful ablation of accessory pathway and atrioventricular nodal re-entrant tachycardia, the U22 protocol
detected a relevant increase in arrhythmia-related well-being. Modest improvement in general well-being was detected by the
SF-36 protocol.
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Introduction
The main indication for ablation of supraventricular
tachycardia (SVTA) is symptomatic relief (1). The
success rate, judged immediately after the inter-
vention, is known to be high (2–4). It has been
shown, however, that even after a primarily success-
ful ablation of accessory pathway many patients
continue to suffer from arrhythmia symptoms (5).
A more appropriate evaluation of procedural success
therefore requires measurement of the symptoms
at follow-up. The SF-36 (Medical Outcomes Study
36-Item Short-Form Health Survey) questionnaire
and other general protocols measure quality of life
and not the paroxysmal symptoms related to arrhyth-
mia. Several arrhythmia-speciﬁc questionnaires have
been described. The Symptom Checklist—Frequency
and Severity Scale (6,7) has been used in ablation
of SVTA, in revised versions in atrial ﬁbrillation
studies (8,9), and in a recent retrospective survey
of late outcome after SVTA (10). The different imple-
mentations of the checklist are less well documented
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applied in atrial ﬁbrillation (Symptom Speciﬁc
Checklist with seven aspects of arrhythmia (11),
Symptom Severity Questionnaire measuring ﬁve
symptom parameters (12), a bedside-oriented ques-
tionnaire with classiﬁcation into four groups (13)).
None of these approaches fulﬁl the requirement of
being well described and commonly accepted for use
in different arrhythmia types.
U22 (Umea 22 Arrhythmia Questions) is a clini-
cally oriented questionnaire, developed for evaluation
of intermittent symptoms related to arrhythmia (see
Appendix). The questionnaire quantiﬁes multiple
self-perceived symptom aspects associated with the
arrhythmic events. In measurements on patients with
SVTA scheduled for catheter ablation, U22 indicates
a prominent discomfort during arrhythmia. Patients
with SVTA that undergo catheter ablation are thus
highly symptomatic, although their general well-
being is only modestly decreased when measured
by SF-36 (14). The SVTA ablation has a distinct
end-point and a high success rate, making this patient
group suitable for testing the questionnaire. In the
present study, we investigate whether the arrhythmia-
speciﬁc symptom questionnaire U22 is better suited
than the generic questionnaire SF-36 for measure-
ment of the clinical improvement after an ablation of
SVTA.
Material and methods
Questionnaires
The arrhythmia-speciﬁc symptoms were measured
with U22 (Swedish form) (14). The Appendix
describes the questionnaire. SF-36, a well documen-
ted instrument (15), was used as a generic measure
of quality of life. It quantiﬁes the mental and physical
well-being in eight subscales with a range of 0–100,
together with a physical and a mental summary
score.
Patients
Patients with SVTA (accessory pathway (AP)
and atrioventricular nodal re-entrant tachycardia
(AVNRT)), admitted for scheduled routine catheter
ablation at the Heart Centre, University Hospital,
Umeå, Sweden during 2006–2008, were invited to
answer the base-line U22 and SF-36 forms. Next day
the diagnosis was established invasively and treated by
catheter ablation. The evaluation with U22 and
SF-36 was repeated 6 months after the ablation.
The answers were prospectively entered into a data-
base and retrieved for the subsequent analysis.
Analysis
First-time interventions for the target diagnoses
were selected. The catheterization reports from all
ablations were reviewed by an experienced operator,
blinded with respect to the U22 results (S.M.J.), and
each procedure was evaluated for primary outcome.
Ablation success in AP was deﬁned as absence of delta
wave and retrograde conduction block in the acces-
sory pathway and in AVNRT as non-inducibility of
tachycardia.
The data were analysed in SPSS, release 13 (SPSS
Inc., Chicago, Illinois). The U22 and SF-36 scores
were compared pairwise at base-line versus at
follow-up in individual patients. Data are presented
as mean ± SD. Differences between continuous
variables were examined by paired and unpaired
t test. Correlations (Spearman’s rho) between indi-
vidual patients’ scores at base-line and follow-up
were used for studying common properties of the
responses in patients with varying symptomatology
and perception of discomfort. Two-tailed Fisher
exact test was used for testing differences in 2  2
table proportions. A P value < 0.05 was considered
signiﬁcant. The study was approved by the Ethics
Committee at the Umeå University Faculty of
Medicine.
Results
Effect of ablation on U22 and SF-36
Between April 2006 and May 2008, 141 patients
underwent 156 ablations for SVTA (1.1 procedure/
patient). From 63 patients undergoing ﬁrst-time abla-
tion for AP or AVNRT, all four forms were available
(U22 and SF-36 at base-line and at the follow-up,
210 ± 35 days after ablation). Table I summarizes the
background data. In 58 of these subjects the ablation
was primarily successful, as judged by the blinded
analysis. The results are summarized in Table II (see
Appendix for deﬁnition of the U22 scores). According
to the verbal deﬁnitions underlying the numerical
score values, the arrhythmias were highly symptom-
atic at base-line, and a marked decrease in the symp-
toms was seen after a successful ablation. The
U22 score for relevance of answers was high both
at base-line and follow-up. The U22 score for general
well-being (question 1) increased from 5.9 ± 2.6 at
base-line to 7.9 ± 1.9 at follow-up (Table II). The
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well-being measured at follow-up (question 2) was
8.2 ± 2.1. The two SF-36 measures physical compo-
nent summary (PCS) and mental component sum-
mary (MCS) increased after ablation from 46.9 ±
9.4 to 48.4 ± 10.7 and from 44.9 ± 12.5 to 49.1 ±
9.9 (P=0.04 and 0.002). For the proﬁle of the eight
SF-36 subscales, see Figure 1.
Correlation between U22 scores before ablation and at
follow-up
The U22 score for well-being at follow-up correlated
to the same score before the ablation (Spearman’s rho
0.59; P < 0.0005). Similarly, a correlation was found
in the time aspect score (rho = 0.32; P=0.03). No
signiﬁcant correlations in the scores before the abla-
tion and at follow-up were found for arrhythmia
affecting the well-being (question 11), discomfort
during a spell (question 12), intensity of dominant
symptom, and width of symptoms (rho = 0.21, 0.12,
0.03, 0.06; P= n.s. for all). The score for well-being
at follow-up was correlated to the pre-ablational
symptoms of irregularity and anxiety during a spell
(questions 15 and 21) (rho = -0.31 and -0.28; P=
0.03 and 0.04). An absence of correlation was noted
between the patients’ retrospective estimation of
improvement in well-being after the ablation (ques-
tion 2follow-up) and the improvement computed from
the two forms as (question 1follow-up – question 1base-
line) (rho = 0.09; P=n.s.).
Medication
At base-line, 71% of the patients did take some
prescribed medication for the arrhythmia (57% in
the AP group and 80% in the AVNRT group). At
follow-up after a primarily successful ablation, 27%
remained on medication (9% in the AP group and
38% in the AVNRT group).
In the two groups of patients on no anti-
arrhythmic medication at follow-up (73%) and
patients on continuing anti-arrhythmic medication
(27%), the U22 score for well-being was 8.0 ± 1.8
Table I. Demographic data.
Patients with all 4 forms
(n = 63)
Patients with 1–3 missing forms
(n = 78)
AP AVNRT AP AVNRT
n 26 37 35 43
Age mean (SD), years 43.9 (17.9) 57.1 (14.0) 42.3 (18.4) 53.3 (17.4)
Men, n (%) 17 (65) 14 (38) 27 (77) 18 (42)
All four requested forms (U22 and SF-36 at base-line and follow-up) were available from 63 of the 141 patients undergoing ﬁrst-time ablations
for AP or AVNRT. Five of the 63 ablations with complete data were not primarily successful, and these patients were subsequently excluded.
AP = accessory pathway; AVNRT = atrioventricular nodal re-entrant tachycardia.
Table II. U22 measures at base-line and follow-up.
Question Base-line Follow-up P (t test)
Well-being q01 5.9 ± 2.6 7.9 ± 1.9 <0.0005
Arrhythmia events affecting well-being q11 7.5 ± 2.8 2.0 ± 3.1 <0.0005
Discomfort during arrhythmia spell q12 8.1 ± 2.2 2.3 ± 3.2 <0.0005
Symptom width
a 2.5 ± 1.7 0.9 ± 1.4 <0.0005
Intensity of dominant symptom 9.9 ± 0.3 3.9 ± 4.6 <0.0005
Incidence of symptoms q08 2.5 ± 1.1 0.9 ± 1.3 <0.0005
Time aspect
b q08, q10 4.7 ± 1.5 1.4 ± 1.8 <0.0005
Relevance score
a q19 9.6 ± 1.5 9.5 ± 1.7 n.s.
Data from 58 ﬁrst-time ablations, classiﬁed as primarily successful.
aSee Appendix for deﬁnition.
bSee Appendix and Table III for deﬁnition.
q01, q08, q10, q11, q12, q19 = U22 questions 1, 8, 10, 11, 12, 19.
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scores for arrhythmia as a cause for impaired well-
being were 1.5 ± 2.8 versus 3.3 ± 3.5 (P=0.06),
discomfort during attack 1.8 ± 2.9 versus 3.5 ±
3.7 (P= 0.09), dominant intensity 3.1 ± 4.5 versus
5.6 ± 4.8 (P=0.09), width of symptoms 0.6 ±
1.1 versus 1.3 ± 1.8 (P=0.1), and time aspect
2.2 ± 2.1 versus 0.9 ± 1.6 (P=0.02). The
SF-36 measures PCSandMCSwere50.6±9.2versus
42.8 ± 12.9 and 51.0 ± 7.8 versus 44.9 ± 13.6,
respectively (P=0.02 and 0.05).
Discussion
We have evaluated U22 as a tool for measurement of
arrhythmia-related symptoms in a well deﬁned group
of patients with paroxysmal supraventricular tachy-
cardia who were undergoing an intervention with a
distinct end-point and a high success rate. The
scores quantifying the arrhythmia symptoms
decreased notably. The improvement in general
well-being was smaller. U22 thus seems to be
more suitable for measuring the effect of ablation
than a general questionnaire, like SF-36. In contrast
to SF-36, the scales of U22 have a clinical
arrhythmia-related meaning, making the question-
naire useful for clinical evaluation of changes in
individual patients.
An important application for the U22 questionnaire
may be in arrhythmias with more diffuse symptom-
atology and interventions with less well deﬁned end-
points, situations occurring in patients with atrial
ﬁbrillation (16,17).
Correlation between U22 scores before ablation and at
follow-up
The absence of correlation between base-line and
follow-up in the scores describing the arrhythmia is
reasonable, in view of a primarily successful ablation.
Surprisingly, the retrospective estimation of improve-
ment in well-being (question 2) was not related to the
computed difference in well-being between base-
line and follow-up. A patient’s retrospective estimate
of improvement after ablation therefore seems doubt-
ful as a measure of ablation success.
SF-36
The proﬁle of the SF-36 subscales at base-line in our
group resembles closely that of another recent
Scandinavian group of patients with SVTA (18).
Both groups have a similar proﬁle to an earlier mate-
rial (6), but on a higher subscale level (Figure 1).
A relation between general quality of life and the
symptom-speciﬁc measures can be expected, since
the arrhythmia-related symptoms are severe enough
to motivate the patients to undergo ablation. This
relation is rather weak in our material,where a marked
decrease of symptom-speciﬁc measures is followed by
a modest increase in the SF-36 measures. This is
presumably due to the relatively high level of quality
of life measured by SF-36 already at base-line, in spite
of a marked arrhythmia-related symptomatology.
A surprisingly large proportion of our patients
remained on medication at follow-up, in spite of a
primarily successful ablation. It has been shown that,
Table III. Computation of the time aspect from the symptom duration and incidence scores.
q08 How often
Never
On rare
occasions
A few times
a month
A few times
a week Daily
All the
time
01 2 3 4 5
q10 How long Seconds 0 0 1 2 3 4 5
Minutes, less than a quarter of an hour 1 0 2 3 4 5 6
A quarter of an hour to one hour 2 – 34 5 6 –
One to four hours 3 – 45 6 7 –
Longer 4 – 56 7 8 9
All the time 5 –– – – 91 0
The time aspect is found by lookingupthe row with relevant symptomdurationscore (q08)and columnwith relevantsymptomincidence score
(q10). For most combinations the time aspect is a simple addition of the two scores (both with range 0–5). The combination of incidence
‘never’ and duration ‘minutes’ is, however, assigned time aspect value 0. The entries marked as ‘–’ are coded as missing values as they
correspond to largely inconsequent combinations of the two scores: Incidence ‘never’ with durations ‘a quarter of an hour’ or more; incidences
‘few times a week’ or less with duration ‘All the time’; incidence ‘All the time’ with durations ‘a quarter of an hour’ to ‘four hours’.
q08 = U22 question 8; q10 = U22 question 10.
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way,39%ofthepatientscontinuedtoreportarrhythmia
symptoms and 8% remained on anti-arrhythmic treat-
ment (5). Corresponding ﬁgures for the patients with
accessory pathways in the present material are very
similar, while an even larger proportion of patients
withAVNRTremainedonanti-arrhythmicmedication.
We lack information from ECG (Electrocardiogra-
phic)-monitoring that would conﬁrm or exclude a rela-
tion of the measured symptoms to an arrhythmia.
Therefore the reason behind the continuing need for
anti-arrhythmicmedicationcannotbedetermined.Our
AVNRT patients had a mean age of 57 years, 13 years
more than the AP group. These middle-aged and
elderly patients are often treated with beta-blockers
orCa-antagonistsforhypertension.Thisisonepossible
explanation for the large proportion of patients that
remain on medication after ablation of AVNRT.
Limitations
The study describes the pattern of paroxysmal symp-
toms, measured by U22 in a group of patients before
and after an ablation. However, we have no data on
the validity and reproducibility of the questionnaire.
For computation of speciﬁcity and sensitivity of the
symptom measurement it would be necessary to relate
the described symptoms to incidence of ECG-
veriﬁed arrhythmia. However, no continuous rhythm
monitoring was performed in the study.
Reference values for the U22 scores from some type
ofcontrolgroupwouldbe desirable.U22 aimsatatype
of speciﬁc symptom-focused measurement that makes
it difﬁcult to construct a proper control group with
normal reference values. The U22 questions make
sense for patients with arrhythmia symptoms or those
that have been cured from an arrhythmia. To achieve
meaninginnormalcontrolsthequestionswouldhaveto
be rephrased. In the present form it is, however, rea-
sonable to view the U22 scores of the subgroup free
from medication at follow-up as representing a refer-
ence level after a successful treatment, since 1) the
indication is based on a combination of symptoms
and invasive electrophysiological diagnosis, and 2)
the treatment can be considered as successful in
patients that have been primarily successfully ablated
and have no anti-arrhythmic medication at follow-up.
The values of the SF-36 parameters PCS and MCS in
this group are very close to 50 (normal).
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Figure 1. SF-36 subscales. The ﬁgure shows the SF-36 proﬁles at base-line and follow-up, labelled with mean values of the eight subscales in
the study group. For comparison, the proﬁles of an older and a recently published group of patients with SVTA (6,18) are shown (the mean
values were derived from the published graph and the number of patients). At base-line, the present study group is very close to the recent
material by Walfridsson et al. (18). The proﬁle is similar, but at a higher absolute subscale level than in the older material of patients by
Bubien et al. (6). This may reﬂect a development towards ablation in patients with fewer symptoms. (pf = physical functioning; rp = role-
physical; bp = bodily pain; gh = general health; vt = vitality; sf = social functioning; re = role-emotional; mh = mental health;
SVTA = supraventricular tachycardia.)
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from the analysis, due to failure to return all the four
forms. The number of forms requested from each
patient was demanding. Two additional factors may
have contributed to the high exclusion rate: the
base-line forms were not collected by speciﬁcally
assigned staff, but as a part of normal patient admis-
sion routines; and in case of missing follow-up forms,
no reminder was sent out. The patients that were
excluded due to missing forms were slightly younger,
with a higher proportion of men (Table I).
The English version of U22 was translated from
Swedish with the intention of corresponding closely
with the original meaning. A translation nevertheless
introduces a source of error into any comparisons.
Comparison of treatments based on different transla-
tions of a questionnaire should therefore be accom-
panied by some evaluation, at least by a comparison of
the initial levels in similar populations.
Conclusion
The U22 questionnaire detected the expected symp-
tomatic improvement in patients ablated with primary
success for AP and AVNRT. A prominent increase
could be seen in measures of arrhythmia-related well-
being. In comparison, the improvement observed in
the generic SF-36 questionnaire was relatively small.
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U22 questionnaire
The U22 instrument aims at quantifying prevalence
and severity of arrhythmia-associated symptoms (14).
It consists of two related questionnaires to be
answered at base-line and follow-up after an inter-
vention, respectively.
Questions about general well-being, the inﬂuence
of arrhythmia on the well-being, and the intensity of
discomfort and speciﬁc symptoms during a spell are
answered by choosing one of 11 alternatives, aligned
in a horizontal line of 10 cm length, with verbal
descriptions of the end-points (anchors). The subject
is instructed to select the answer by placing an X in
the circle that best reﬂects how he feels. The answers
are translated to a discrete numeric rating scale with
range of 0–10 (NRS-10) (Numerical Rating Scale, a
discrete analogy to the common VAS [Visual Ana-
logue Scale]).
The scores give an estimate of well-being, the effect
of arrhythmia events on the well-being, discomfort
during a spell, and the maximal symptom intensity.
A symptom width score is computed as the number of
dominant symptoms (the symptoms rated as having
equal, maximal intensity). The symptom width score
is set to 0 if the subject disagrees to some degree with
all symptom descriptions, i.e. all the scores from
questions 11–22 are <5. The subject’s understanding
and relevancy of the answers is tested by question
19 about itching, a symptom irrelevant in the context
of arrhythmias. A relevance score is computed as
(10 – scale 19).
The incidence and duration of the events is esti-
mated by questions 8 and 10 with 6 non-linear answer
alternatives, quantiﬁed as 0–5. A time aspect score
with a range of 0–10 is computed by adding the two
answer scores (Table III).
Base-line form (English translation of the original
Swedish forms used in the study)
The answer choices are stated within the square
brackets.
1. On the whole, how have you felt over the past month? [Miserable–very well, 0–10]
(2 – not applicable in base-line form)
3. Do you take any prescribed medications for your
heart rhythm problems?
[No; Yes]
4. How effective is the medication(s) in treating your
heart rhythm problems?
[Very much worse–very much better, 0–10]
5. How much are you bothered by side-effects of the medication? [Not at all–very much, 0–10]
(6, 7 – not applicable in base-line form)
8. How often do you experience problems with heart rhythm?
(despite taking any medication)
[Never; Rarely; A few times a month; A few times
a week; Daily; All the time]
9. Do the spells start suddenly? [No; Yes]
10. How long does a spell usually last? [Seconds; More than a minute but less than 15 min;
15 min to 1 hour; 1 to 4 hours; More than 4 hours; All the time]
11. How much do the spells affect your well-being? [Not at all–very much, 0–10]
12. How bothered are you while you are experiencing a spell? [Not at all–very much, 0–10]
13. My heart beats extremely fast when I’m having a spell [Not at all–very true, 0–10]
14. My heart pounds very heavily when I’m having a spell [Not at all–very true, 0–10]
15. My heart beats very irregularly when I’m having a spell [Not at all–very true, 0–10]
16. I faint or feel extremely dizzy when I’m having a spell [Not at all–very true, 0–10]
17. I have terrible pain when I’m having a spell [Not at all–very true, 0–10]
18. I feel extremely tired when I’m having a spell [Not at all–very true, 0–10]
19. I feel like my skin itches all over when I’m having a spell [Not at all–very true, 0–10]
20. I feel extremely short of breath when I’m having a spell [Not at all–very true, 0–10]
21. I become very frightened when I’m having a spell [Not at all–very true, 0–10]
22. Someone close to me becomes very frightened when
I’m having a spell
[Not at all–very true, 0–10]
58 M. Kesek et al.Follow-up form. The follow-up questionnaire is
equivalent to the base-line form, with an addi-
tion of three questions that explore the type of
remaining symptoms (question 6) and the pre-
sent general well-being and arrhythmia symp-
tomatology in comparison to base-line (questions 2
and 7).
Questions 7–22 in the follow-up form are only
answered if the patient in question 6 indicates any
remaining problems with the heart rhythm. If the
patient has no such problems, no further answers
are requested, and on analysis the scores for questions
8 and 10–22 will be set to 0, while question 7 will be
set to 10.
2. Compared to the time before the treatment, do you now feel: [Very much worse–very much better, 0–10]
6. Have you experienced any problems with the heart rhythm
after the treatment? (Please disregard the ﬁrst 3 months after
the treatment.)
[No; Yes, of the same type as before the treatment;
Yes, of different type]
7. How bothersome are the spells in comparison with those before
the treatment?
[Very much more–very much less, 0–10]
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